About ESWI2025

Programme

Programme

The programme is subject to change.

0
Sun 19 Oct 2025
17:00 - 20:00
 
Mon 20 Oct 2025
09:00 - 18:00
10:00 - 11:00
PLE
Plenary opening and keynotes PLE01
Auditorium 1 - Plenary Hall
Chairs
Colin RUSSELL
ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
Read more
Ab OSTERHAUS
ESWI Board Member, TiHO, Germany
Read more
Stefania MAGGI
ESWI Board Member, National Research Council of Italy, Italy
Read more
Marco GOEIJENBIER
ESWI Board Member, Spaarne Gasthuis, Netherlands
Read more
Ended Now live Upcoming
  1. Opening word by the conference chairs: The 10th ESWI Influenza Conference
    Colin RUSSELLESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
  2. Opening address by the Spanish Minister of Health
    Mónica GARCÍA GÓMEZSpanish Ministry of Health, Spain
  3. Long Covid
    Peter OPENSHAWESWI Board Member, Imperial College, United Kingdom
  4. H5N1 bovine outbreaks in the USA
    Stacey SCHULTZ-CHERRYSt Jude Children's Research Hospital, United States
  5. Closing remarks
    Colin RUSSELLESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
    Ab OSTERHAUSESWI Board Member, TiHO, Germany
    Stefania MAGGIESWI Board Member, National Research Council of Italy, Italy
    Marco GOEIJENBIERESWI Board Member, Spaarne Gasthuis, Netherlands
11:00 - 11:30
Coffee Break COF01
Exhibition hall
Ended Now live Upcoming
11:30 - 13:00
SCS
Innate and adaptive immunity SCS01
Auditorium 1 - Plenary Hall
Chairs
Guus RIMMELZWAAN
University of Veterinary Medicine, Hannover, Germany
Read more
Kevin SELVA
Doherty Institute, University of Melbourne, Australia
Read more
Ended Now live Upcoming
  1. Opening of the session
    Guus RIMMELZWAANUniversity of Veterinary Medicine, Hannover, Germany
    Kevin SELVADoherty Institute, University of Melbourne, Australia
  2. 1. Increasing SARS-CoV-2 IgG4 following repeated mRNA boosters negatively impact antibody functions across Omicron variants and sarbecoviruses
    Kevin SELVADoherty Institute, University of Melbourne, Australia
  3. 2. Impact of Aging on CD8+ T Cell Immunity to Circulating and Pandemic Viruses
    Carolien VAN DE SANDTESWI Associate Member, Murdoch Children’s Research Institute, Melbourne, Australia
  4. 3. Detection of pre-existing humoral immunity against influenza virus H5N1 clade 2.3.4.4b in unexposed individuals
    Christoph KREERUniversity of Cologne, Germany
  5. 4. Systemic and mucosal antibody signatures of protection against sars-cov-2 transmission
    Amaya ROJO FERNANDEZIcahn School of Medicine at Mount Sinai, United States
  6. 5. Obesity modulates tracheal and cardiac responses to influenza A virus infection
    Betina Lyngfeldt HENRIKSENTechnical University of Denmark, Denmark
  7. 6. Prior influenza vaccination shapes subsequent vaccine responses in a randomized placebo-controlled trial
    Marcos VIEIRAUniversity of Chicago, United States
  8. Closing remarks
    Guus RIMMELZWAANUniversity of Veterinary Medicine, Hannover, Germany
    Kevin SELVADoherty Institute, University of Melbourne, Australia
SCS
Pandemic Preparedness SCS02
Auditorium 2 - Breakout
Chairs
Ab OSTERHAUS
ESWI Board Member, TiHO, Germany
Read more
Nico Joel HALWE
Ludwig Boltzmann Gesellschaft, Austria
Ended Now live Upcoming
  1. Opening of the session
    Ab OSTERHAUSESWI Board Member, TiHO, Germany
    Nico Joel HALWELudwig Boltzmann Gesellschaft, Austria
  2. 1. Observed Immunogenicity After Two Doses of an MF59-Adjuvanted Cell Culture–Derived H5N8 Influenza Vaccine (aH5N8c) in Healthy Subjects Aged ≥18 Years
    Janine OBERIJECSL R&D - Vaccines Innovation Unit, Netherlands
  3. 2. Immunogenicity of Homologous or Heterologous Booster Vaccinations with MF59-Adjuvanted, Cell Culture–Derived H5N8 or H5N6 Influenza Vaccines in Healthy Subjects Aged ≥18 Years
    Eve VERSAGECSL Seqirus, United States
  4. 3. When can sequence data confirm transmission links in respiratory virus outbreaks?
    Simon DE JONGAmsterdam University Medical Centers, Netherlands
  5. 4. Broad-Spectrum Baseline Immunity Against Highly Pathogenic Avian Influenza A(H5N1) Clade 2.3.4.4b Viruses in Dutch Healthcare Workers: Insights into Both Humoral and Cellular Immune Responses
    Mark POWERErasmus Medical Center, Netherlands
  6. 5. Evaluating Cross-Protective Antibody Responses to Influenza A(H5N8) Vaccine in High-Risk Groups
    Oona LIEDESFinnish Institute for Health and Welfare, Finland
  7. 6. OVX836, a Nucleoprotein based vaccine under clinical development, offers protection against Highly Pathogenic Avian Influenza viruses (H5N1 and H7N9) in mouse and ferret models
    Charlotte PRIMARDOsivax, France
  8. Closing remarks
    Ab OSTERHAUSESWI Board Member, TiHO, Germany
    Nico Joel HALWELudwig Boltzmann Gesellschaft, Austria
SPI
ESWI invites coalition partners: Life Course Immunisation: A Seamless Approach to Protection Across All Ages SPI01
Auditorium 3 - Breakout
Chairs
Stefania MAGGI
ESWI Board Member, National Research Council of Italy, Italy
Read more
Catherine WEIL OLIVIER
independent expert, Trustee of CLCI, France
Read more
Ended Now live Upcoming
  1. Understanding life course immunisation
    Stefania MAGGIESWI Board Member, National Research Council of Italy, Italy
    Catherine WEIL OLIVIERindependent expert, Trustee of CLCI, France
  2. Age-specific immunisation needs and challenges
    Paula TÄHTINENESWI Board Member, Turku University Hospital and University of Turku, Finland
    Nicola VERONESEUnicamillus University, Italy
  3. Burden of disease
    Catherine MOOREPublic Health Wales, United Kingdom
  4. Nurses and Pharmacists as Immunisation Champions
    George KASSIANOSESWI Board Member, United Kingdom
    Lars-Åke SÖDERLUNDInternational Pharmaceutical Federation, Sweden
  5. Barriers & Solutions for Seamless Life Course Immunisation: Interactive Discussion
    Catherine WEIL OLIVIERindependent expert, Trustee of CLCI, France
    Stefania MAGGIESWI Board Member, National Research Council of Italy, Italy
    Paula TÄHTINENESWI Board Member, Turku University Hospital and University of Turku, Finland
    Nicola VERONESEUnicamillus University, Italy
    Catherine MOOREPublic Health Wales, United Kingdom
    George KASSIANOSESWI Board Member, United Kingdom
    Lars-Åke SÖDERLUNDInternational Pharmaceutical Federation, Sweden
  6. Call to Action and Closing Remarks
    Catherine WEIL OLIVIERindependent expert, Trustee of CLCI, France
    Stefania MAGGIESWI Board Member, National Research Council of Italy, Italy
13:00 - 14:30
Lunch LUN01
Exhibition hall
Ended Now live Upcoming
13:15 - 14:15
SAT
Satellite Symposium organised by AstraZeneca: Unfolding the story of the immune response to an intranasal live attenuated influenza vaccine SAT01
Auditorium 2 - Breakout
Chair
Peter OPENSHAW
ESWI Board Member, Imperial College, United Kingdom
Read more
Ended Now live Upcoming
  1. Welcome and introduction
    Peter OPENSHAWESWI Board Member, Imperial College, United Kingdom
  2. MOVE-ing forward: towards a better understanding of mucosal immunity and correlates of protection for a live attenuated influenza vaccine
    Yper HALLUKHSA, United Kingdom
  3. Mucosal immunity matters: mechanistic insights into a live attenuated influenza vaccine
    Ryan THWAITESNational Heart and Lung Institute, Imperial College London, United Kingdom
  4. Beyond antigenic match: optimizing candidate virus strain selection for a live attenuated influenza vaccine
    Oliver DIBBENAstraZeneca, United Kingdom
  5. Q&A and meeting close
    Peter OPENSHAWESWI Board Member, Imperial College, United Kingdom
14:30 - 16:00
SCS
Future vaccination strategies - PART 1 SCS03
Auditorium 1 - Plenary Hall
Chairs
Florian KRAMMER
ESWI Board Member, Medical University of Vienna, Austria
Read more
Yona TUGG
McMaster University, Canada
Read more
Ended Now live Upcoming
  1. Opening of the session
    Florian KRAMMERESWI Board Member, Medical University of Vienna, Austria
    Yona TUGGMcMaster University, Canada
  2. 1. A Dendritic Cell-targeting Approach to Deliver a Universal Influenza Vaccine Candidate to the Respiratory Mucosa
    Daryl LEENational University of Singapore, Singapore
  3. 2. Development of a next-generation COVID-19 intranasal vaccine based on a multivalent NDV-HXP-S formulation.
    Marta BOZA CUENCAIcahn School of Medicine at Mount Sinai, United States
  4. 3. Superior protection and prevention of transmission upon influenza infection by adjuvanted mucosal vaccination in the guinea pig influenza model.
    Michael SCHOTSAERTIcahn School of Medicine at Mount Sinai, United States
  5. 4. Broad betacoronavirus immunity and SARS-CoV-2 protection induced by divergent spike-based nucleoside-modified vaccines
    Anass ABBADIcahn Medical School at Mount Sinai, United States
  6. 5. The Additive Effect of Neuraminidase Inclusion in Influenza Vaccine Formulations using a Self-Amplifying RNA Platform
    Giuseppe PALLADINOCSL, United States
  7. 6. Evaluation of a broadly protective influenza B virus vaccine based on mosaic hemagglutinin platforms in mice.
    Irene GONZÁLEZ-DOMÍNGUEZIcahn School of Medicine at Mount Sinai, United States
  8. Closing remarks
    Florian KRAMMERESWI Board Member, Medical University of Vienna, Austria
    Yona TUGGMcMaster University, Canada
SCS
Virus and host factors in pathogenesis - PART 1 SCS04
Auditorium 2 - Breakout
Chairs
Debby VAN RIEL
ESWI Associate Member, Erasmus MC, Netherlands
Read more
Anders MADSEN
Haukeland University Hospital, Norway
Read more
Ended Now live Upcoming
  1. Opening of the session
    Debby VAN RIELESWI Associate Member, Erasmus MC, Netherlands
    Anders MADSENHaukeland University Hospital, Norway
  2. 1. Avian influenza viruses re-shape the hormonal landscape by inducing pulmonary CYP19A1 expression in golden hamsters
    Sebastian BECKLeibniz Institute of Virology, Germany
  3. 2. Obesity increases the risk for severe COVID 19 – An obese hamster model to study sex-specific differences in the underlying pathophysiology
    Zoé SCHMALLeibniz Institute of Virology, Germany
  4. 3. Functional Balance of HA and NA in Emerging Porcine Influenza A Viruses: Sialoreceptor Dynamics at the Mucosal Interface
    Mengying LIUUtrecht University, Netherlands
  5. 4. Cell Tropism, Replication Dynamics, and effect on neural network activity to Seasonal and Pandemic Influenza A Virus Infection in a hiPSC-Derived Neural Co-Culture Model
    Feline BENAVIDESErasmus MC, Netherlands
  6. 5. Single-cell profiling of inflammatory lung injury in clade 2.3.4.4b H5N1 influenza infected mice
    Ying LIUThe University of Hong Kong, Hong Kong SAR China
  7. 6. A history of obesity increases influenza severity via innate immune training in a canonical NLRP3-dependent manner
    Katina HULMEAmsterdam UMC, Netherlands
  8. Closing remarks
    Debby VAN RIELESWI Associate Member, Erasmus MC, Netherlands
    Anders MADSENHaukeland University Hospital, Norway
SPI
Burden of disease in acute respiratory virus infections SPI02
Auditorium 3 - Breakout
Chairs
Paula TÄHTINEN
ESWI Board Member, Turku University Hospital and University of Turku, Finland
Read more
Stefania MAGGI
ESWI Board Member, National Research Council of Italy, Italy
Read more
Ended Now live Upcoming
  1. Welcome and introduction
    Paula TÄHTINENESWI Board Member, Turku University Hospital and University of Turku, Finland
    Stefania MAGGIESWI Board Member, National Research Council of Italy, Italy
  2. Overview of burden of disease in acute respiratory viruses
    Ivan SANZ-MUÑOZInstituto de Estudios de Ciencias de la Salud de Castilla y León, Spain
  3. 1. Risk factors associated with severe health outcomes among older adults hospitalized with respiratory syncytial virus (RSV): understanding the pre-vaccine era landscape
    Vajini ATUKORALEUniversity of Toronto, Canada
  4. Respiratory infections and associated long-term complications
    Fiona ECARNOTUniversity Hospital Besancon, France
  5. Global Status of Adult Immunisation Post COVID-19
    Alba VILAJELIUWHO, Switzerland
  6. Panel discussion
    Paula TÄHTINENESWI Board Member, Turku University Hospital and University of Turku, Finland
    Stefania MAGGIESWI Board Member, National Research Council of Italy, Italy
    Fiona ECARNOTUniversity Hospital Besancon, France
    Alba VILAJELIUWHO, Switzerland
    Vajini ATUKORALEUniversity of Toronto, Canada
  7. Closing remarks
    Paula TÄHTINENESWI Board Member, Turku University Hospital and University of Turku, Finland
    Stefania MAGGIESWI Board Member, National Research Council of Italy, Italy
16:00 - 16:30
Coffee Break COF02
Exhibition hall
Ended Now live Upcoming
16:30 - 17:30
SAT
Satellite Symposium organised by Pfizer: Preventing RSV Disease in Adults: A Vaccination Success Story SAT03
Auditorium 2 - Breakout
Chair
Jorge DEL DIEGO SALAS
General Directorate of Public Health and Health Equity of the Ministry of Health of Spain, Spain
Read more
Ended Now live Upcoming
  1. Welcome and Introduction
    Jorge DEL DIEGO SALASGeneral Directorate of Public Health and Health Equity of the Ministry of Health of Spain, Spain
  2. RSV Disease in Adults: The Hidden Burden and Advancing Prevention
    Giovanni CHECCUCCI LISIPFIZER, Italy
  3. RSV Disease Prevention: A Story of Success in the UK
    George KASSIANOSESWI Board Member, United Kingdom
  4. Beyond Respiratory Protection: Latest Real-World Evidence for the Bi-valent RSVpreF Vaccine (DAN-RSV)
    Mats C. Højbjerg LASSENHerlev og Gentofte Hospital, Denmark
  5. Summary and Q&A
    Jorge DEL DIEGO SALASGeneral Directorate of Public Health and Health Equity of the Ministry of Health of Spain, Spain
SAT
Satellite Symposium organised by the ESWI IDC and supported by IFPMA and Sanofi: When Infections Meet NCDs: The Bidirectional Relationship Between Cardiometabolic Conditions and Respiratory Viruses SAT11
Auditorium 3 - Breakout
Chair
Marco GOEIJENBIER
ESWI Board Member, Spaarne Gasthuis, Netherlands
Read more
Ended Now live Upcoming
  1. The Bidirectional Relationship Between Cardiometabolic Conditions and Respiratory Viruses why and now?
    Marco GOEIJENBIERESWI Board Member, Spaarne Gasthuis, Netherlands
  2. 1. When Glucose Swings Matter: Glycemic Variability and Influenza Outcomes in Critically Ill Patients
    Ramon FLUITSpaarne Ziekenhuis: Spaarne Gasthuis, Netherlands
  3. From Evidence to Gaps: Chronic Conditions Shaping Outcomes in Respiratory Virus Infections what we know, don’t know and want to know
    Kirsty SHORTESWI Associate Member, University of Queensland, Australia
  4. Obesity’s Impact on Infection & Vaccination response; Could obesity be the key link connecting NCDs and increased susceptibility to respiratory infections
    Stacey SCHULTZ-CHERRYSt Jude Children's Research Hospital, United States
  5. From Infection to NCD and Back: Clinical Implications of a Bidirectional Relationship
    Oana SANDULESCUCarol Davila University of Medicine and Pharmacy, National Institute for Infectious Diseases Prof Dr Matei Bals, Romania
  6. Barriers to Vaccination Uptake in High-Risk Groups – and Practical Advice for Clinicians and Policymakers
    Eric C.M. VAN GORPErasmus MC, Netherlands
  7. Questions and discussion with the audience and panellists
    Marco GOEIJENBIERESWI Board Member, Spaarne Gasthuis, Netherlands
17:30 - 19:00
18:30 - 20:00
 
Tue 21 Oct 2025
08:15 - 09:15
SAT
Satellite Symposium: : A Shot in the Arm: Leveraging Combination Vaccines for Global Health Impact (a PeerVoice symposium supported by an educational grant from Moderna) SAT05
Auditorium 2 - Breakout
Ended Now live Upcoming
  1. Welcome and introductions
    Colin RUSSELLESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
  2. The Power of Combination: A New Era in Vaccination
    Colin RUSSELLESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
  3. The Persistent Threat of COVID-19 and Influenza – Why Smarter Vaccination Strategies Are Essential
    John WATKINSCardiff University/Public Health Wales, United Kingdom
  4. Harnessing mRNA Innovation to Advance Combination Vaccines and Improve Uptake
    John WATKINSCardiff University/Public Health Wales, United Kingdom
  5. The Case for Combination Vaccines
    Gili REGEV-YOCHAYSheba Medical Center, Tel Aviv University, Israel
  6. Ask the Faculty and Take-Home Messages
    Colin RUSSELLESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
    John WATKINSCardiff University/Public Health Wales, United Kingdom
    Gili REGEV-YOCHAYSheba Medical Center, Tel Aviv University, Israel
09:30 - 10:30
PLE
Science, Public Health, and Funding in a changing world PLE02
Auditorium 1 - Plenary Hall
Chairs
Ab OSTERHAUS
ESWI Board Member, TiHO, Germany
Read more
Joseph BRESEE
Task Force for Global Health, United States
Read more
Ended Now live Upcoming
  1. Introduction to the session
    Ab OSTERHAUSESWI Board Member, TiHO, Germany
    Joseph BRESEETask Force for Global Health, United States
  2. Short presentations and panel discussion
    Florian KRAMMERESWI Board Member, Medical University of Vienna, Austria
    Peter MARKSIndependent Consultant, United States
    Carolien VAN DE SANDTESWI Associate Member, Murdoch Children’s Research Institute, Melbourne, Australia
    Frederic BOUDERUniversity of Stavanger, Norway
    Nick BUNDLEECDC, Sweden
    Angela RASMUSSENUniversity of Saskatchewan, Canada
10:30 - 11:00
Coffee Break COF03
Exhibition hall
Ended Now live Upcoming
11:00 - 12:30
SCS
Epidemiology and surveillance SCS05
Auditorium 1 - Plenary Hall
Chairs
Marco DEL RICCIO
University of Florence, Italy
Read more
Ended Now live Upcoming
  1. Opening of the session
    Nick BUNDLEECDC, Sweden
    Marco DEL RICCIOUniversity of Florence, Italy
  2. 1. Age at First Influenza A Virus Infection in Children and Impact of Influenza Vaccination
    Kayla HANSONUniversity of Michigan School of Public Health, United States
  3. 2. Association of influenza viral genetic information with disease severity markers in hospitalized patients
    Aung Pone MYINTUCBL1, France
  4. 3. Population-based Surveillance shows Burden of Hospitalisations and Severe Disease due to hMPV, RSV, and Influenza in Older Adults
    Alejandro ORRICO-SÁNCHEZFisabio-Public Health, Spain
  5. 4. Impact of COVID-19 non-pharmaceutical interventions on antibody waning and the resurgence of human respiratory syncytial virus, seasonal coronavirus and influenza virus in a prospective cohort in The Netherlands
    Channah GAASBEEKRIVM, Netherlands
  6. 5. Epidemiology of hospitalizations in older adults with lab-confirmed hMPV infection: A 14-year time series
    Ivan SANZ-MUÑOZInstituto de Estudios de Ciencias de la Salud de Castilla y León, Spain
  7. 6. Epidemiology of human coronaviruses and impact of SARS-CoV-2 vaccination in paediatric patients in Hong Kong
    Zirui GUOThe University of Hong Kong, Hong Kong SAR China
  8. Closing remarks
    Nick BUNDLEECDC, Sweden
    Marco DEL RICCIOUniversity of Florence, Italy
SCS
Molecular virology: Virus evolution, strain selection, structure and replication SCS16
Auditorium 2 - Breakout
Chairs
Sylvie VAN DER WERF
ESWI Associate Member, Institut Pasteur, France
Read more
Jurre SIEGERS
Institut Pasteur du Cambodge, Cambodia
Read more
Ended Now live Upcoming
  1. Opening of the session
    Sylvie VAN DER WERFESWI Associate Member, Institut Pasteur, France
    Jurre SIEGERSInstitut Pasteur du Cambodge, Cambodia
  2. 1. Antigenic drift in the receptor binding site of H1N1 balances antibody evasion and receptor binding
    Jenna GUTHMILLERUniversity of Colorado Anschutz Medical Campus, United States
  3. 2. HA Mutations Driving Immune Escape in Avian Influenza Virus Do Not Enhance Human Receptor Binding
    Elsayed ABDEL-WHABFriedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Germany
  4. 3. Multivalent Colocalization of Influenza Polymerase and Nucleoprotein by ANP32A Reveals the Molecular Basis of Human Adaptation
    Aldo Roman CAMACHO ZARCOCEA, France
  5. 4. Molecular basis of 60 years of antigenic evolution of human influenza A(H3N2) virus neuraminidase
    Ron FOUCHIERErasmus MC, Netherlands
  6. 5. Little evidence for additional mammalian adaptation in bovine-derived H5N1 viruses during replication or transmission in ferrets
    Heather MACHKOVECHUniversity of Wisconsin, United States
  7. Closing remarks
    Sylvie VAN DER WERFESWI Associate Member, Institut Pasteur, France
    Jurre SIEGERSInstitut Pasteur du Cambodge, Cambodia
SPI
How scientific evidence guides policy: lessons learned SPI03
Auditorium 3 - Breakout
Chairs
Joseph BRESEE
Task Force for Global Health, United States
Read more
Ann MOEN
Task Force for Global Health, United States
Read more
Ended Now live Upcoming
  1. Preventing RSV infections in infants: vaccines and monoclonal antibodies
    Federico MARTINÓN TORRESHospital Clínico Universitario de Santiago de Compostela, Spain
    Ignacio ESTEBANGavi, the Vaccine Alliance, Switzerland
  2. NITAGs and Evidence for Influenza Vaccine Recommendations in Middle Income Countries
    Lisandro TORRETask Force for Global Health, United States
    Stephen HADLERTask Force for Global Health, United States
    Silvia BINOSECID INSTITUTE OF PUBLIC HEALTH ALBANIA, Albania
12:30 - 14:00
Lunch LUN02
Exhibition hall
Ended Now live Upcoming
12:45 - 13:45
SAT
Satellite Symposium organised by Sanofi: Aim High, SHOOT the FLU with a Better SHOT! SAT06
Auditorium 2 - Breakout
Ended Now live Upcoming
  1. Welcome and introduction
    Colin RUSSELLESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
  2. Real-world evidence (RWE) for influenza vaccine effectiveness: The GOOD and the BAD!
    Mathieu BANGERTSanofi, France
  3. Results and learnings from the largest ever individually randomised influenza vaccine effectiveness study: FLUNITY-HD
    Federico MARTINÓN TORRESHospital Clínico Universitario de Santiago de Compostela, Spain
  4. Panel discussion and closing remarks
    Colin RUSSELLESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
    Mathieu BANGERTSanofi, France
    Federico MARTINÓN TORRESHospital Clínico Universitario de Santiago de Compostela, Spain
14:00 - 15:30
SCS
Pharmaceutical and non pharmaceutical interventions SCS07
Auditorium 1 - Plenary Hall
Chairs
Benjamin COWLING
The University of Hong Kong, Hong Kong SAR China
Read more
Nisreen OKBA
Icahn School of Medicine at Mount Sinai, United States
Read more
Ended Now live Upcoming
  1. Opening of the session
    Benjamin COWLINGThe University of Hong Kong, Hong Kong SAR China
    Nisreen OKBAIcahn School of Medicine at Mount Sinai, United States
  2. 1. Estimated Relative Effectiveness and Public Health Impact of Cell-Based Versus Egg Based Influenza Vaccines During the 2023–2024 Season in the United States
    Alicia STEINCSL Seqirus, Australia
  3. 2. Effectiveness of 2024/25 COVID-19 vaccines against symptomatic SARS-CoV-2 infection in the target group for vaccination, European VEBIS primary care multicentre study, autumn/winter 2024/25
    Esther KISSLINGEpiconcept, France
  4. 3. Differential protection of prior infection and repeated vaccination against SARS-CoV-2 infection in Omicron BA.2 to JN.1 predominance: a prospective cohort study
    Nicole Ngai Yung TSANGThe University of Hong Kong, Hong Kong SAR China
  5. 4. Vaccine effectiveness against medically attended influenza at primary care level in the paediatric population, 2024/25 season, Europe
    Héloïse LUCACCIONIEpiconcept, France
  6. 5. Immunogenicity and safety of high dose formulations of mf59-adjuvanted cell-derived influenza vaccine in adults aged 50 years and older: two phase 2 randomised controlled trials
    Frank ALBANOCSL Seqirus, Australia
  7. 6. High-dose recombinant influenza vaccines induce greater A(H3N2)-reactive antibodies and overcome attenuation associated with repeated vaccination compared to standard-dose egg- or cell-based vaccines: results from a RCT in healthy younger adults
    Sheena SULLIVANMonash University, Australia
  8. Closing remarks
    Benjamin COWLINGThe University of Hong Kong, Hong Kong SAR China
    Nisreen OKBAIcahn School of Medicine at Mount Sinai, United States
SCS
Mathematical modelling and projections, including limitations SCS08
Auditorium 2 - Breakout
Chairs
Colin RUSSELL
ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
Read more
Weijia XIONG
The University of Hong Kong, Hong Kong SAR China
Read more
Ended Now live Upcoming
  1. Opening of the session
    Colin RUSSELLESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
    Weijia XIONGThe University of Hong Kong, Hong Kong SAR China
  2. 1. A Framework for Measuring Population Immunity Against Influenza Using Individual Antibody Titers
    Weijia XIONGThe University of Hong Kong, Hong Kong SAR China
  3. 2. serojump: A Bayesian tool for inferring infection timing and antibody kinetics from longitudinal serological data
    Adam KUCHARSKILondon School of Hygiene & Tropical Medicine, United Kingdom
  4. 3. Integrating Serology and PCR to Infer RSV Infection Dynamics and Correlates of Protection in a Community Cohort in The Gambia
    Thushan DE SILVAUniversity of Sheffield, United Kingdom
  5. 4. Joint reconstruction of influenza A(H1N1) and A(H3N2) antibody dynamics to estimate the risk of influenza virus infection
    Tim TSANGThe University of Hong Kong, Hong Kong SAR China
  6. 5. Investigating the predictive power of machine learning algorithms for antigenic novelty of influenza H3 viruses
    Lucy GREENWOODUniversity of Oxford, United Kingdom
  7. 6. Comparative Pre-symptomatic Transmission Potential of Influenza A and SARS-CoV-2 in Households
    Chengyao ZHANGUniversity of Hong Kong, Hong Kong SAR China
  8. Closing remarks
    Colin RUSSELLESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
    Weijia XIONGThe University of Hong Kong, Hong Kong SAR China
SPI
Implementation of adult and risk groups national immunisation programmes SPI04
Auditorium 3 - Breakout
Chairs
Ted VAN ESSEN
ESWI Board Member, Netherlands
Read more
George KASSIANOS
ESWI Board Member, United Kingdom
Read more
Ended Now live Upcoming
  1. Introduction to the session
    Ted VAN ESSENESWI Board Member, Netherlands
    George KASSIANOSESWI Board Member, United Kingdom
  2. 1. Effectiveness of Maternal Influenza Vaccination in Preventing Influenza Infection in Infants Aged ≤ 6 Months in Korea
    Yoonsun YOONKorea University Guro Hospital, South Korea
  3. 2. Preliminary observation of impact of Maternal RSV Vaccination on Infant Hospitalizations in Mendoza, Argentina: A Comparative Study of the 2023 and 2024 Seasons
    Juan Manuel FERNANDEZ MUÑOZMinistry of Health of Mendoza, Argentina
  4. Implementing Adult Vaccination in Europe: Lessons from the AIB Meeting
    Marco DEL RICCIOUniversity of Florence, Italy
  5. Strengthening Immunisation Systems for Equity and Resilience in the WHO European Region
    Oleg BENESWHO RO for Europe, Denmark
  6. SPI Roundtables in Europe Lessons from Czech Republic and Austria
    Roman PRYMULAESWI Board Member, Postgraduate Medical School, Czechia
    Florian KRAMMERESWI Board Member, Medical University of Vienna, Austria
  7. Discussion and wrap up
    Ted VAN ESSENESWI Board Member, Netherlands
    George KASSIANOSESWI Board Member, United Kingdom
    Yoonsun YOONKorea University Guro Hospital, South Korea
    Juan Manuel FERNANDEZ MUÑOZMinistry of Health of Mendoza, Argentina
    Marco DEL RICCIOUniversity of Florence, Italy
    Oleg BENESWHO RO for Europe, Denmark
    Florian KRAMMERESWI Board Member, Medical University of Vienna, Austria
    Roman PRYMULAESWI Board Member, Postgraduate Medical School, Czechia
15:30 - 16:00
Coffee Break COF04
Exhibition hall
Ended Now live Upcoming
16:00 - 17:00
SAT
Satellite Symposium organised by CSL Seqirus: Addressing the evolving influenza landscape: a public health imperative SAT07
Auditorium 2 - Breakout
Chair
Colin RUSSELL
ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
Read more
Ended Now live Upcoming
  1. Navigating change: Current challenges with preventable respiratory viruses
    Colin RUSSELLESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
  2. Targeting age-related immune decline with enhanced influenza vaccines
    Paolo BONANNIUniversity of Florence, Italy
  3. Advancing technologies for influenza prevention in children and adults
    Tino SCHWARZKlinikum Wuerzburg Mitte, Germany
  4. Final remarks and Q&A
    Colin RUSSELLESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
    Paolo BONANNIUniversity of Florence, Italy
    Tino SCHWARZKlinikum Wuerzburg Mitte, Germany
17:00 - 18:30
18:30 - 19:30
 
Wed 22 Oct 2025
08:15 - 09:15
SAT
Satellite Symposium organised by the Global Influenza Initiative: Preventing influenza to safeguard ageing populations SAT08
Auditorium 2 - Breakout
Chair
Litjen (L.J) TAN
Co-Chair of the Global Influenza Initiative; Immunize.org, United States
Read more
Ended Now live Upcoming
  1. Welcome and setting the scene
    Litjen (L.J) TANCo-Chair of the Global Influenza Initiative; Immunize.org, United States
  2. Navigating the 2024-2025 flu season: insights on severity, vaccine uptake and impact
    Litjen (L.J) TANCo-Chair of the Global Influenza Initiative; Immunize.org, United States
    Mine DURUSU TANRIOVERDirector of Vaccine Institute, Hacettepe University, Türkiye
  3. Understanding what shapes influenza vaccine decisions by HCPs and patients
    Salah AL AWAIDIPublic Health Consultant, Oman
    Litjen (L.J) TANCo-Chair of the Global Influenza Initiative; Immunize.org, United States
    Mine DURUSU TANRIOVERDirector of Vaccine Institute, Hacettepe University, Türkiye
    George KASSIANOSESWI Board Member, United Kingdom
  4. Strengthening partnerships for lifelong wellness
    Salah AL AWAIDIPublic Health Consultant, Oman
    Litjen (L.J) TANCo-Chair of the Global Influenza Initiative; Immunize.org, United States
    Mine DURUSU TANRIOVERDirector of Vaccine Institute, Hacettepe University, Türkiye
    George KASSIANOSESWI Board Member, United Kingdom
  5. Summary and close
    Litjen (L.J) TANCo-Chair of the Global Influenza Initiative; Immunize.org, United States
09:30 - 10:30
PLE
Keynote Lectures PLE03
Auditorium 1 - Plenary Hall
Chair
Stefania MAGGI
ESWI Board Member, National Research Council of Italy, Italy
Read more
Ended Now live Upcoming
  1. From Questions to Insights: Advancing Respiratory Virus Epidemiology in the Spirit of John Paget
    Marco DEL RICCIOUniversity of Florence, Italy
  2. Silent reservoirs for long term consequences of ARVI
    Gülsah GABRIELESWI Board Member, Leibniz Institute of Virology, Germany
  3. Understanding Viral and Antibody Kinetics to Strengthen Influenza and COVID-19 Surveillance and Control
    Adam KUCHARSKILondon School of Hygiene & Tropical Medicine, United Kingdom
10:30 - 11:00
Coffee Break COF05
Exhibition hall
Ended Now live Upcoming
11:00 - 12:30
SCS
Future vaccination strategies - PART 2 SCS09
Auditorium 1 - Plenary Hall
Chairs
Florian KRAMMER
ESWI Board Member, Medical University of Vienna, Austria
Read more
Marios KOUTSAKOS
University of Melbourne, Australia
Read more
Ended Now live Upcoming
  1. Opening of the session
    Florian KRAMMERESWI Board Member, Medical University of Vienna, Austria
    Marios KOUTSAKOSUniversity of Melbourne, Australia
  2. 1. A Novel Antigenically Central HA mRNA Vaccine Confers Humoral and Cellular Immune Responses and Protects Ferrets Against Challenge With a Heterologous A(H5) Clade 2.3.4.4b Highly Pathogenic Avian Influenza Virus
    Willemijn RIJNINKErasmus MC, Netherlands
  3. 2. Breast milk-derived secretory IgA provides broad protection against influenza A virus
    Yona TUGGMcMaster University, Canada
  4. 3. Hemagglutination inhibition antibody titer as correlate of protection against influenza virus infection: a systematic review and meta-analysis
    Nancy H. L. LEUNGThe University of Hong Kong, Hong Kong SAR China
  5. 4. Pooled Long-Term Safety Analysis of a Phase 1/2/3 Randomized, Observer-Blind, Controlled Study of the Self-Amplifying mRNA COVID-19 Vaccine ARCT-154 in Adults
    Josephine VAN BOXMEERCSL Seqirus, Netherlands
  6. 5. Decades of Evidence Revisited: A Systematic Review on Anti-Neuraminidase Antibody Responses and Influenza-related Outcomes
    Clotilde SÉBLAINSanofi vaccines, France
  7. 6. Immunogenicity and Reactogenicity of an mRNA-Based Seasonal Influenza and SARS-CoV-2 Multicomponent Vaccine (mRNA-1083) in Adults ≥65 Years With Comorbidities
    Lusine KOSTANYANModerna, Inc., United States
  8. Closing remarks
    Florian KRAMMERESWI Board Member, Medical University of Vienna, Austria
    Marios KOUTSAKOSUniversity of Melbourne, Australia
SCS
Human challenge studies SCS11
Auditorium 2 - Breakout
Chair
Ab OSTERHAUS
ESWI Board Member, TiHO, Germany
Read more
Ended Now live Upcoming
  1. Opening of the session
    Ab OSTERHAUSESWI Board Member, TiHO, Germany
  2. 1. Disease characteristics and immunological profiles obtained from a newly developed hMPV human challenge model
    Brandon LONDThVIVO, United Kingdom
  3. 2. Evolution of Human Metapneumovirus (HMPV) over the last 20 years and superior isolation of HMPV from clinical samples in organoid-derived bronchial cell cultures to isolation in monolayer cell line cultures
    Bernadette VAN DEN HOOGENErasmusMC, Netherlands
  4. 3. A Study of the Efficacy, Safety and Immunogenicity of mRNA vaccines in an Influenza B Challenge Model in Healthy Adults
    Anita GEEVARUGHESEPfizer, United States
  5. 4. Development of a Severe Acute Respiratory Syndrome – Coronavirus 2 (SARS-CoV-2) Omicron BA5 human challenge model (HCM) for the assessment of new vaccine and anti-viral therapies in seropositive subjects
    Alex MANNhVIVO, United Kingdom
  6. 5. Establishing a Controlled Human Infection Model with a contemporary Respiratory Syncytial Virus B challenge agent in healthy volunteers
    Victor CNOSSENCentre for Human Drug Research, Netherlands
  7. Closing remarks
    Ab OSTERHAUSESWI Board Member, TiHO, Germany
SCS
Clinical Manifestations, burden of disease and management SCS10
Auditorium 3 - Breakout
Chairs
Marco GOEIJENBIER
ESWI Board Member, Spaarne Gasthuis, Netherlands
Read more
Valentino D'ONOFRIO
Ghent University, Belgium
Read more
Ended Now live Upcoming
  1. Opening of the session
    Marco GOEIJENBIERESWI Board Member, Spaarne Gasthuis, Netherlands
    Valentino D'ONOFRIOGhent University, Belgium
  2. 1. Burden of Influenza Hospitalisation (Including With Recent COVID-19) Among Individuals With Immunocompromising Conditions and Other Comorbidities: An Exploratory Analysis Using the INFORM Study Cohort
    Wilhelmine MEERAUSAstraZeneca, United Kingdom
  3. 2. Is clinical outcome pathogen related? Characteristics and Outcomes of ICU Patients with Severe Acute Respiratory Infections: Focusing on Respiratory Syncytial Virus, Human Metapneumovirus, Influenza virus, and Parainfluenza virus
    Sjoerd VAN DER BIESpaarne Gasthuis, Netherlands
  4. 3. Hospital Burden of Respiratory Syncytial Virus (RSV) in Adults Aged 18 to 60 Years in France: A Nationwide Analysis (2018–2023)
    Clarisse DEMONTModerna, France
  5. 4. Clinical outcomes among older adults hospitalized with respiratory syncytial virus and influenza infection – a retrospective study from Israel
    Michal MANDELBOIMIsrael Ministry of Health, Israel
  6. 5. The Effect of Revaccination and Reinfection on Symptom Severity and Prevalence in a Post Covid-19 Condition Cohort
    Emma VAN DER SPEKNational Institute for Public Health and the Environment (RIVM), Netherlands
  7. 6. RSV in Patients with Hematological Malignancies: A Multi-centre Retrospective Cohort Study
    Justin DUTOITWits Donal Gordon Medical Center, South Africa
  8. Closing remarks
    Marco GOEIJENBIERESWI Board Member, Spaarne Gasthuis, Netherlands
    Valentino D'ONOFRIOGhent University, Belgium
12:30 - 14:00
Lunch LUN03
Exhibition hall
Ended Now live Upcoming
12:45 - 13:45
SAT
Satellite Symposium Communicating for Change – Innovative Strategies to Boost Adult Immunisation (an ESWI symposium supported by an educational grant from GSK) SAT09
Auditorium 2 - Breakout
Chair
Frederic BOUDER
University of Stavanger, Norway
Read more
Ended Now live Upcoming
  1. Introduction and scope of the session
    Frederic BOUDERUniversity of Stavanger, Norway
  2. Silent Signals: Structural Ageism, Vaccine Policy, and the Call for Reciprocal Communication
    Jane BARRATTDr Jane Barratt Consulting Inc, Canada
  3. Trust as Infrastructure: Equity, Empathy, and Evidence in Shaping Sustainable Immunisation Strategies
    Rodrigo SCOTINIInfectious Disease Alliance (IDA), Denmark
  4. Grassroots Mobilisation Leveraging Civil Society and Community Leadership to Bridge Gaps in Vaccine Coverage
    Mariano VOTTAActive Citizenship Network, Italy
  5. Embedding Vaccine Communication in Everyday Health: Lessons from EU Initiatives
    Barbara RATHVaccine Safety Initiative, Germany
  6. Panel and Audience Exchange: Addressing Structural Ageism, Trust, and Vaccine Confidence
    Barbara RATHVaccine Safety Initiative, Germany
    Jane BARRATTDr Jane Barratt Consulting Inc, Canada
    Rodrigo SCOTINIInfectious Disease Alliance (IDA), Denmark
    Mariano VOTTAActive Citizenship Network, Italy
14:00 - 15:30
SCS
Antiviral and immune therapy SCS12
Auditorium 1 - Plenary Hall
Chairs
Adolfo GARCÍA-SASTRE
Icahn School of Medicine at Mount Sinai, United States
Read more
Josefine SCHROEDER
Jena University Hospital, Germany
Read more
Ended Now live Upcoming
  1. Opening of the session
    Adolfo GARCÍA-SASTREIcahn School of Medicine at Mount Sinai, United States
    Josefine SCHROEDERJena University Hospital, Germany
  2. 1. Effectiveness of the approved antiviral drugs for mild/moderate infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Hong Kong
    George OKOLIThe University of Hong Kong, Hong Kong SAR China
  3. 2. Impact of Antiviral Timing and Vaccination on Viral Shedding in Hospitalized Older Adults with COVID-19 During Omicron Predominance
    Yun LINWorld Health Organization Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region, China, Hong Kong SAR China
  4. 3. Analysis of potential drug combinations against influenza by specifically targeting the viral polymerase
    Bahaaeldin ALHAMMADYLeibniz-Institut für Virologie (LIV), Germany
  5. 4. Treatment with pictilisib-loaded lipid nanoparticles reduces influenza A virus infection in vitro and ex vivo
    Josefine SCHROEDERJena University Hospital, Germany
  6. 5. Comparative assessment of in vivo antiviral activity of anti-influenza drugs (AD ASTRA)
    Podjanee JITTAMALAMahidol University, Thailand
  7. 6. Structural characterization and preclinical development of a heavy chain-only antibody that protects against group 1 and group 2 influenza A viruses
    Xavier SAELENSGhent University and VIB, Belgium
  8. Closing remarks
    Adolfo GARCÍA-SASTREIcahn School of Medicine at Mount Sinai, United States
    Josefine SCHROEDERJena University Hospital, Germany
SCS
Virus evolution and strain selection SCS13
Auditorium 2 - Breakout
Chairs
Kirsty SHORT
ESWI Associate Member, University of Queensland, Australia
Read more
Kairat TABYNOV
Kazakh National Agrarian Research University, Kazakhstan
Read more
Ended Now live Upcoming
  1. Opening of the session
    Kirsty SHORTESWI Associate Member, University of Queensland, Australia
    Kairat TABYNOVKazakh National Agrarian Research University, Kazakhstan
  2. Avian influenza in Australia's native aviafauna
    Kirsty SHORTESWI Associate Member, University of Queensland, Australia
  3. 1. Antigenic mapping of influenza A viruses using deep learning-based prediction of hemagglutination inhibition titers
    Bingyi YANGThe University of Hong Kong, Hong Kong SAR China
  4. 2. Site specific predictability of amino acid substitutions of seasonal influenza viruses
    Annelies DE ROOIJAmsterdam University Medical Center, Netherlands
  5. 3. Informal settlements and COVID-19: viral phylodynamic, respiratory microbiome, and public health implications.
    Mercedes Soledad NABAES JODARRicardo Gutierrez Children Hospital, Argentina
  6. 4. Understanding the evolution of Influenza A/H3N2 polymerase complex
    Carla LOURENSAmsterdam UMC - Locatie AMC, Netherlands
  7. Closing remarks
    Kirsty SHORTESWI Associate Member, University of Queensland, Australia
    Kairat TABYNOVKazakh National Agrarian Research University, Kazakhstan
SPI
Transdisciplinary Approaches for Pandemic Preparedness SPI05
Auditorium 3 - Breakout
Chair
Ed HUTCHINSON
ESWI Board Member, University of Glasgow, United Kingdom
Read more
Ended Now live Upcoming
  1. Introduction to the session
    Ed HUTCHINSONESWI Board Member, University of Glasgow, United Kingdom
  2. Leibniz Lab Pandemic Preparedness - a German Initiative for Pandemic Preparedness
    Gülsah GABRIELESWI Board Member, Leibniz Institute of Virology, Germany
  3. The Pandemic and Disaster Preparedness Center (PDPC) as a Dutch Initiative for Pandemic Preparedness
    Ron FOUCHIERErasmus MC, Netherlands
  4. Epistemic Exclusion in Science Communication
    Mona SIMIONUniversity of Glasgow, United Kingdom
  5. Prepared Together: Co-Creative Research for Future Pandemics
    Sabine MAASENUniversität Hamburg, Germany
  6. Panel discussion
    Gülsah GABRIELESWI Board Member, Leibniz Institute of Virology, Germany
    Sabine MAASENUniversität Hamburg, Germany
    Mona SIMIONUniversity of Glasgow, United Kingdom
    Ron FOUCHIERErasmus MC, Netherlands
  7. Closing remarks
    Ed HUTCHINSONESWI Board Member, University of Glasgow, United Kingdom
15:30 - 16:00
Coffee Break COF06
Exhibition hall
Ended Now live Upcoming
16:00 - 17:30
SCS
Threats from the animal world SCS14 PLE
Auditorium 1 - Plenary Hall
Chairs
Stacey SCHULTZ-CHERRY
St Jude Children's Research Hospital, United States
Read more
Kevin CIMINSKI
University Medical Center Freiburg, Germany
Read more
Ended Now live Upcoming
  1. Opening of the session
    Stacey SCHULTZ-CHERRYSt Jude Children's Research Hospital, United States
    Kevin CIMINSKIUniversity Medical Center Freiburg, Germany
  2. Keynote address: Zoonotic Influenza: Emerging Threats from the Animal World
    Martin BEERFriedrich-Loeffler-Institut, Germany
  3. 1. Genomic insights into the broadening host range of clade 2.3.4.4b H5 avian influenza viruses
    Alice FUSAROIstituto Zooprofilattico Sperimentale delle Venezie, Italy
  4. 2. Emergence of a Novel Reassortant Clade 2.3.2.1e Avian Influenza A/H5N1 Virus Associated with Human Cases in Cambodia
    Jurre SIEGERSInstitut Pasteur du Cambodge, Cambodia
  5. 3. Increased attachment to and replication of recent avian H5N1 influenza A viruses from clade 2.3.4.4b in human airway epithelial cells
    Lisa BAUERErasmus MC, Netherlands
  6. 4. Bovine Myxovirus Resistance Protein 1 mediates antiviral activity against human and avian influenza A viruses
    Rubaiyea FARRUKEEUniversity of Melbourne, Australia
  7. Closing remarks
    Stacey SCHULTZ-CHERRYSt Jude Children's Research Hospital, United States
    Kevin CIMINSKIUniversity Medical Center Freiburg, Germany
17:30 - 19:00
 
Thu 23 Oct 2025
08:15 - 09:15
SAT
Satellite Symposium organised by Pfizer: Unlocking the value of vaccines as a tool to support the management of non-communicable diseases (NCDs) SAT10
Auditorium 1 - Plenary Hall
Chair
Jane BARRATT
Dr Jane Barratt Consulting Inc, Canada
Read more
Ended Now live Upcoming
  1. Welcome and introduction
    Jane BARRATTDr Jane Barratt Consulting Inc, Canada
  2. The burden of co-circulating vaccine-preventable respiratory diseases
    Charles FELDMANUniversity of the Witwatersrand, Australia
  3. The impact of vaccine-preventable respiratory infections on non-communicable diseases
    Stefania MAGGIESWI Board Member, National Research Council of Italy, Italy
  4. Advocacy levers to help drive vaccine uptake in eligible populations
    Michael MOOREWorld Federation of Public Health Associations, Australia
  5. Audience Q&A and Panel Discussion
    Jane BARRATTDr Jane Barratt Consulting Inc, Canada
SAT
Satellite Symposium organised by the ENDFLU project: Evaluation of rationally designed influenza vaccines - EU Horizon 2020 research and innovation programme SAT12
Auditorium 2 - Breakout
Chair
Ab OSTERHAUS
ESWI Board Member, TiHO, Germany
Read more
Ended Now live Upcoming
  1. Development of Modified Vaccinia virus Ankara (MVA)-based influenza vaccines for pandemic preparedness targeting hemagglutinin of selected influenza A virus subtypes
    Alina TSCHERNEMedical University of Vienna, Austria
  2. Design and evaluation of a poly-epitope based vaccine for the induction of influenza A virus cross-reactive CD8 + T cell responses
    Guus RIMMELZWAANUniversity of Veterinary Medicine, Hannover, Germany
  3. Influenza A virus NA as an antiviral target
    Xander DE HAANUtrecht University, Netherlands
09:30 - 10:30
ECAS
Early Career Scientist Awards and Presentations ECAS03 PLE
Auditorium 1 - Plenary Hall
Chairs
Carolien VAN DE SANDT
ESWI Associate Member, Murdoch Children’s Research Institute, Melbourne, Australia
Read more
Colin RUSSELL
ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
Read more
Ended Now live Upcoming
  1. Award Ceremony
    Colin RUSSELLESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
    Carolien VAN DE SANDTESWI Associate Member, Murdoch Children’s Research Institute, Melbourne, Australia
  2. DEI Awards Science Slam
    Fiseha Wadilo WADAArmaour Hansen Research Institute, Ethiopia
    Shiyamalee ARUNASALAMUniversity of Peradeniya, Sri Lanka
    Aida ABBASIReNAp company, Iran
    Norosoa Harline RAZANAJATOVOInstitut Pasteur de Madagascar, Madagascar
    Sètondji Islamiath KISSIRANational Laboratory of Hemorrhagics and Virals Fevers of Bénin (LFHV), Benin
  3. Another receptor, another tropism: Lessons from bats as influenza A virus reservoirs
    Kevin CIMINSKIUniversity Medical Center Freiburg, Germany
  4. Antigenic evolution of influenza B viruses
    Marios KOUTSAKOSUniversity of Melbourne, Australia
10:30 - 11:00
Coffee Break COF07
Exhibition hall
Ended Now live Upcoming
11:00 - 12:30
SCS
Virus Structure and replication SCS06
Auditorium 1 - Plenary Hall
Chairs
Ed HUTCHINSON
ESWI Board Member, University of Glasgow, United Kingdom
Read more
Lisa BAUER
Erasmus MC, Netherlands
Read more
Ended Now live Upcoming
  1. Opening of the session
    Ed HUTCHINSONESWI Board Member, University of Glasgow, United Kingdom
    Lisa BAUERErasmus MC, Netherlands
  2. 1. Proteomic analysis of the subcellular reorganization during Influenza A infection in human cells
    Laura GADEA-SALOMBIOTECMED, Universitat de València, Spain
  3. 2. Influenza NS1-Mediated N(6)-Methyladenosine Modification Controls NS mRNA Splicing
    Yingyin LIAOThe University of Hong Kong, Hong Kong SAR China
  4. 3. Reassortment dynamics between clade 2.3.2.1 and 2.3.4.4b A(H5) influenza viruses
    Lorin ADAMSThe Francis Crick Institute, United Kingdom
  5. 4. Human respirovirus infection driven by heteromultivalent binding of sialoglycotopes
    Xander DE HAANUtrecht University, Netherlands
  6. 5. RSV Polymerase L Recruits Rab11a to Facilitate Ribonucleoprotein Transport
    Marie-Anne RAMEIX-WELTIInstitut Pasteur CNR Vir (Bat Jacob, France
  7. 6. Transient RNA structure-driven insertions in H5 hemagglutinin required for highly pathogenic avian influenza virus genesis are not dependent on polymerase origin.
    Roy M. HUTCHINSONErasmus MC, Netherlands
  8. Closing remarks
    Ed HUTCHINSONESWI Board Member, University of Glasgow, United Kingdom
    Lisa BAUERErasmus MC, Netherlands
SCS
Virus and host factors in pathogenesis - PART 2 SCS17
Auditorium 2 - Breakout
Chairs
Ron FOUCHIER
Erasmus MC, Netherlands
Read more
Mengying LIU
Utrecht University, Netherlands
Read more
Ended Now live Upcoming
  1. Opening of the session
    Ron FOUCHIERErasmus MC, Netherlands
    Mengying LIUUtrecht University, Netherlands
  2. 1. Respiratory Syncytial Virus G Protein Enhances Viral Dissemination Through TLR2-NFκB-Mediated NLRP3 Priming and Pyroptotic Cell Death
    Robert MEINEKEUniversity of Veterinary Medicine Hannover, Germany
  3. 2. Reverse Zoonosis Shapes Transmission and Virulence of Recent H5N1 Clade 2.3.4.4b in Diverse Bird Species
    Elsayed ABDEL-WHABFriedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Germany
  4. 3. Autoantibodies against type I IFNs in patients with zoonotic H7N9 infection
    Martin SCHWEMMLEUniversity of Freiburg, Germany
  5. 4. Revealing Fc-functional antibody landscapes in COVID-19
    Teresa AYDILLO GOMEZIcahn School of Medicine of Mount Sinai Hospital, United States
  6. 5. Knockdown of Irf9 within vagal sensory ganglia exacerbates disease severity during pulmonary influenza A viral infection
    Nathalie VERZELEUniversity of Melbourne, Belgium
  7. 6. Genome-wide CRISPR/Cas9 screen identifies host factors potentially modulating influenza A virus polymerase fidelity
    Hui Min LEEThe Roslin Institute, United Kingdom
  8. Closing remarks
    Ron FOUCHIERErasmus MC, Netherlands
    Mengying LIUUtrecht University, Netherlands
12:30 - 14:00
14:00 - 15:30
SCS
Late Breakers: novel and outstanding discoveries SCS15 PLE
Auditorium 1 - Plenary Hall
Chairs
Sylvie VAN DER WERF
ESWI Associate Member, Institut Pasteur, France
Read more
Carolien VAN DE SANDT
ESWI Associate Member, Murdoch Children’s Research Institute, Melbourne, Australia
Read more
Ended Now live Upcoming
  1. Opening of the session
    Sylvie VAN DER WERFESWI Associate Member, Institut Pasteur, France
    Carolien VAN DE SANDTESWI Associate Member, Murdoch Children’s Research Institute, Melbourne, Australia
  2. 1. mRNA-1010, an mRNA-Based Influenza Vaccine, is Safe and Efficacious in Adults Aged ≥50 Years, Including Individuals at High Risk for Severe Disease
    Rituparna DASModerna Therapeutics, United States
  3. 2. A real-life study revealed the presence of more than 10% nirsevimab escape mutants in RSV-B breakthrough infections.
    Marie-Anne RAMEIX-WELTIInstitut Pasteur CNR Vir (Bat Jacob, France
  4. 3. Adjuvanted inactivated zoonotic influenza A(H5N8) vaccination induces antibody and T-cell responses to emerging HPAI clade 2.3.4.4b A(H5N1) viruses in healthcare workers
    Rory DE VRIESErasmus MC, Netherlands
  5. 4. Translational efficacy of CD388, a novel Drug Fc-Conjugate (DFC), in mouse influenza infection models: application to prevention efficacy in the recently completed Ph2b NAVIGATE clinical study
    Voon ONGCidara, United States
  6. 5. Effectiveness of HD-IIV against laboratory-confirmed influenza infection and patient-centered outcomes in the community: a DANFLU-2 sub-study
    Filip Soeskov DAVIDOVSKIHerlev and Gentofte Hospital, Denmark
  7. 6. Novel Drug-Antigen Conjugate EV25: Results from a First-in-Human Phase 1/2a Trial in Healthy Volunteers and H3N2 Influenza Challenge Participants - Safety, Pharmacokinetics and Antiviral Activity
    Jeffery NIELSENEradivir, United States
  8. Closing remarks
    Sylvie VAN DER WERFESWI Associate Member, Institut Pasteur, France
    Carolien VAN DE SANDTESWI Associate Member, Murdoch Children’s Research Institute, Melbourne, Australia
15:40 - 15:55
PLE
Keynote lecture PLE05
Auditorium 1 - Plenary Hall
Chair
Marco GOEIJENBIER
ESWI Board Member, Spaarne Gasthuis, Netherlands
Read more
Ended Now live Upcoming
  1. The FLUNITY-HD study, a prespecified pooled analysis of the DANFLU-2 and GALFLU trials
    Tor BIERING-SØRENSENUniversity of Copenhagen, Denmark
16:00 - 16:20
PLE
Closing remarks PLE04
Auditorium 1 - Plenary Hall
Chairs
Colin RUSSELL
ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
Read more
Ab OSTERHAUS
ESWI Board Member, TiHO, Germany
Read more
Stefania MAGGI
ESWI Board Member, National Research Council of Italy, Italy
Read more
Marco GOEIJENBIER
ESWI Board Member, Spaarne Gasthuis, Netherlands
Read more
Ended Now live Upcoming
  1. Closing remarks and reveal of the 11th ESWI Conference location
    Colin RUSSELLESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
    Ab OSTERHAUSESWI Board Member, TiHO, Germany
    Marco GOEIJENBIERESWI Board Member, Spaarne Gasthuis, Netherlands
    Stefania MAGGIESWI Board Member, National Research Council of Italy, Italy
 

Programme chairs

Ab OSTERHAUS
BIO
Ab OSTERHAUS
ESWI Board Member, TiHO, Germany
Adolfo GARCÍA-SASTRE
BIO
Adolfo GARCÍA-SASTRE
Icahn School of Medicine at Mount Sinai, United States
Anders MADSEN
BIO
Anders MADSEN
Haukeland University Hospital, Norway
Ann MOEN
BIO
Ann MOEN
Task Force for Global Health, United States
Benjamin COWLING
BIO
Benjamin COWLING
The University of Hong Kong, Hong Kong SAR China
Carolien VAN DE SANDT
BIO
Carolien VAN DE SANDT
ESWI Associate Member, Murdoch Children’s Research Institute, Melbourne, Australia
Catherine WEIL OLIVIER
BIO
Catherine WEIL OLIVIER
independent expert, Trustee of CLCI, France
Colin RUSSELL
BIO
Colin RUSSELL
ESWI Board Member, Academic Medical Center, University of Amsterdam, Netherlands
Debby VAN RIEL
BIO
Debby VAN RIEL
ESWI Associate Member, Erasmus MC, Netherlands
Ed HUTCHINSON
BIO
Ed HUTCHINSON
ESWI Board Member, University of Glasgow, United Kingdom
Florian KRAMMER
BIO
Florian KRAMMER
ESWI Board Member, Medical University of Vienna, Austria
Frederic BOUDER
BIO
Frederic BOUDER
University of Stavanger, Norway
George KASSIANOS
BIO
George KASSIANOS
ESWI Board Member, United Kingdom
Guus RIMMELZWAAN
BIO
Guus RIMMELZWAAN
University of Veterinary Medicine, Hannover, Germany
Jane BARRATT
BIO
Jane BARRATT
Dr Jane Barratt Consulting Inc, Canada
Jorge DEL DIEGO SALAS
BIO
Jorge DEL DIEGO SALAS
General Directorate of Public Health and Health Equity of the Ministry of Health of Spain, Spain
Josefine SCHROEDER
BIO
Josefine SCHROEDER
Jena University Hospital, Germany
Joseph BRESEE
BIO
Joseph BRESEE
Task Force for Global Health, United States
Jurre SIEGERS
BIO
Jurre SIEGERS
Institut Pasteur du Cambodge, Cambodia
Kairat TABYNOV
BIO
Kairat TABYNOV
Kazakh National Agrarian Research University, Kazakhstan
Kevin CIMINSKI
BIO
Kevin CIMINSKI
University Medical Center Freiburg, Germany
Kevin SELVA
BIO
Kevin SELVA
Doherty Institute, University of Melbourne, Australia
Kirsty SHORT
BIO
Kirsty SHORT
ESWI Associate Member, University of Queensland, Australia
Lisa BAUER
BIO
Lisa BAUER
Erasmus MC, Netherlands
Litjen (L.J) TAN
BIO
Litjen (L.J) TAN
Co-Chair of the Global Influenza Initiative; Immunize.org, United States
Marco DEL RICCIO
BIO
Marco DEL RICCIO
University of Florence, Italy
Marco GOEIJENBIER
BIO
Marco GOEIJENBIER
ESWI Board Member, Spaarne Gasthuis, Netherlands
Marios KOUTSAKOS
BIO
Marios KOUTSAKOS
University of Melbourne, Australia
Mengying LIU
BIO
Mengying LIU
Utrecht University, Netherlands
Nick BUNDLE
BIO
Nick BUNDLE
ECDC, Sweden
Nico Joel HALWE
Nico Joel HALWE
Ludwig Boltzmann Gesellschaft, Austria
Nisreen OKBA
BIO
Nisreen OKBA
Icahn School of Medicine at Mount Sinai, United States
Paula TÄHTINEN
BIO
Paula TÄHTINEN
ESWI Board Member, Turku University Hospital and University of Turku, Finland
Peter OPENSHAW
BIO
Peter OPENSHAW
ESWI Board Member, Imperial College, United Kingdom
Ron FOUCHIER
BIO
Ron FOUCHIER
Erasmus MC, Netherlands
Ruxandra DRAGHIA-AKLI
BIO
Ruxandra DRAGHIA-AKLI
Novavax, Inc., United States
Stacey SCHULTZ-CHERRY
BIO
Stacey SCHULTZ-CHERRY
St Jude Children's Research Hospital, United States
Stefania MAGGI
BIO
Stefania MAGGI
ESWI Board Member, National Research Council of Italy, Italy
Sylvie VAN DER WERF
BIO
Sylvie VAN DER WERF
ESWI Associate Member, Institut Pasteur, France
Ted VAN ESSEN
BIO
Ted VAN ESSEN
ESWI Board Member, Netherlands
Valentino D'ONOFRIO
BIO
Valentino D'ONOFRIO
Ghent University, Belgium
Weijia XIONG
BIO
Weijia XIONG
The University of Hong Kong, Hong Kong SAR China
Yona TUGG
BIO
Yona TUGG
McMaster University, Canada